Cosmo Pharmaceuticals reported encouraging long-term results for its experimental male hair loss treatment. The treatment showed sustained hair growth and a strong safety profile after one year of clinical use. The company said its topical drug, clascoterone, delivered continued hair regrowth in men with androgenetic alopecia, a common form of male pattern baldness. The findings come from an extension of ...